Recombinant Human AT-rich interactive domain-containing protein 1A(ARID1A),partial

In Stock
Code CSB-EP002058HU1
Size US$2466
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP002058HU1 could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) ARID1A.
  • Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP002058HU1 could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) ARID1A.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 85% as determined by SDS-PAGE.
Target Names ARID1A
Uniprot No. O14497
Research Area Cancer
Alternative Names actin-dependent regulator of chromatin subfamily F member 1; ARI1A_HUMAN; ARID domain containing protein 1A; ARID domain-containing protein 1A; ARID1A; AT rich interactive domain 1A (SWI like); AT rich interactive domain 1A; AT rich interactive domain containing protein 1A; AT-rich interactive domain-containing protein 1A; B120; BAF250; BAF250A; BM029; brain protein 120 ; BRG1 associated factor 250; BRG1 associated factor 250a; BRG1-associated factor 250; BRG1-associated factor 250a; C1ORF4; chromatin remodeling factor p250 ; chromosome 1 open reading frame 4; ELD; hELD; hOSA1; matrix-associated; MRD14; Osa homolog 1; OSA1; OSA1 nuclear protein ; P270; SMARCF1; SWI like protein; SWI SNF complex protein p270; SWI-like protein; SWI/SNF complex protein p270; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily f, member 1; SWI/SNF-related
Species Homo sapiens (Human)
Source E.coli
Expression Region 1976-2231aa
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 33.4 kDa
Protein Length Partial
Tag Info N-terminal 10xHis-tagged and C-terminal Myc-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 3-7 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Binds DNA non-specifically. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity).
Gene References into Functions
  1. Cells lacking ARID1A show enhanced AURKA transcription, which leads to the persistent activation of CDC25C, a key protein for G2/M transition and mitotic entry. PMID: 30097580
  2. the correlation between the loss of ARID1A immunoreactivity and reduced ARID1B levels indicates that ARID1B could be an attractive target for anti-cancer therapy. PMID: 29890703
  3. these data suggest that the combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib may be a promising therapeutic regimen for the treatment of gastric cancer, and ARID1A deficiency could serve as a potential predictive therapeutic biomarker. PMID: 29767248
  4. Although Genome-Wide Association studies have not been carried out in the field of alcohol-related hepatocellular carcinoma (HCC), common single nucleotide polymorphisms conferring a small increase in the risk of liver cancer risk have been identified. Specific patterns of gene mutations including CTNNB1, TERT, ARID1A and SMARCA2 exist in alcohol-related HCC. [review] PMID: 28296015
  5. The authors find that ARID1A has a dominant role in maintaining chromatin accessibility at enhancers, while the contribution of ARID1B is evident only in the context of ARID1A mutation. PMID: 28967863
  6. ARID1A and human epidermal growth factor receptor-2 (Her-2) status were found to be independent prognostic factors of both overall survival (OS) and disease free survival (DFS). PMID: 28543794
  7. ARID1A expression loss was associated with poor overall survival in Asians with gastric cancer. [meta-analysis] PMID: 27354232
  8. the significant correlation was achieved between the negative ARID1A expression and the FIGO stage of endometrium-related gynecological cancers, but not the other characteristics. PMID: 28466574
  9. This metaanalysis indicated that Gastric Cancer or Colorectal Cancer with ARID1A alteration might be a marker of poor prognosis. The ARID1A alteration of Gastric Cancer may result from different epigenetic factors. PMID: 28937020
  10. Low ARID1A expression is associated with clear cell and endometrioid carcinoma of the ovary and the endometrium. PMID: 29451900
  11. Loss of PTEN and ARID1A expression is highly specific for malignancy in effusion pathology PMID: 29170871
  12. We propose a signaling cascade involving ARID1A, GADD45B and DUSP1 as mediators of the romidepsin effects in GCC cells. PMID: 27572311
  13. head and neck squamous cell carcinoma patients with tumors having high level of miR-31 expression and high levels of Nanog/OCT4/Sox2/EpCAM expression, together with low level of ARID1A expression, were found to have the worst survival PMID: 27528032
  14. loss of ARID1A leads to accumulation of ROS; elesclomol may be used to target ARID1A-mutant gynecologic cancer cells PMID: 27486766
  15. genomic data and clinical features of four patients carrying a small 1p36.11 microduplication encompassing the complete ARID1A gene PMID: 27906199
  16. Data show that 38 samples of 82 ovarian clear cell carcinoma (CCC) specimens presented no BAF250a expression, and 50 samples exhibited the loss of at least one subunit of the SWI/SNF complex. PMID: 27340867
  17. Partial loss (i.e. in one tissue section some cells stained positive for BAF250a while other cells, usually an adjacent group, were negative) of BAF250a protein was identified in 36% (9/25) of rectovaginal DIE samples, 40% (2/5) of endometriosis lesions involving the PSLN, 30% (6/20) of endometriomas, and also in 25% (5/20) of endometrium from controls. PMID: 26832958
  18. In the very high-risk Bladder Cancer patients , several genes had a higher frequency of mutations than reported in the The Cancer Genome Atlas database, including ARID1A . Mutation associations with receipt of neoadjuvant chemotherapy, nodal involvement, metastatic disease development, and survival were analyzed. PMID: 27520487
  19. Tumors accumulate ARID1A mutations. PMID: 27172896
  20. ARID1A silencing could significantly enhance the capability of migration and invasion in lentivirus miR-144-3p cells. PMID: 29073615
  21. we identified concurrent ARID1A and ARID1B inactivating mutations with consequent loss of protein expression in the undifferentiated component of approximately one-quarter of dedifferentiated endometrial and ovarian carcinomas PMID: 27562491
  22. Our study provides a novel insight into the modulatory function and mechanism of ARID1A in PI3K/AKT signaling in gastric cancer PMID: 27323812
  23. Of the 34 undifferentiated endometrial carcinomas examined, 17 (50%) exhibited SWI/SNF complex inactivation, with 11 tumors showing complete loss of both ARID1A and ARID1B, 5 showing complete loss of BRG1 and 1 showing complete loss of INI1. Ten of the remaining 17 undifferentiated carcinomas showed the following alterations: 5 tumors (15%) showed loss of ARID1A only with intact ARID1B, BRG1, and INI1 expression. PMID: 28863077
  24. BAF250a loss in AE is consistently associated with the development of BAF250a-negative endometriosis-associated cancers and appears to be an early event in most of these cases. PMID: 27051059
  25. Transcriptome analysis revealed ARID1A knockdown led to miR-503 upregulation. CDKN2A was identified as a target of miR-503, which contributes to cell senescence. Thus, the data suggests that ARID1A deficiency promote KRAS(G12D)-driven pancreatic tumorigenesis through miR-503/CDKN2A-mediated senescence. PMID: 28942143
  26. ARID1A may be a primary driver of carcinogenesis in a subset of esophageal adenocarcinomas PMID: 28440661
  27. ARID1A mutation inactivates the apoptosis-promoting function of p53 by upregulating HDAC6, indicating that pharmacological inhibition of HDAC6 is a therapeutic strategy for ARID1A-mutated cancers. PMID: 28737768
  28. ARID1A mutation can be an early stage event in the oncogenic transformation of endometriosis cells giving rise to ovarian clear cell carcinoma. PMID: 28483516
  29. ARID1A expression is significantly decreased in higher stages of urothelial carcinoma and its aggressive variants. PMID: 27137986
  30. Our data suggests that deficiency or loss of functional mutations of ARID1A in HCC cells might contribute to the increased activity of certain cancer-promoting lncRNAs. PMID: 28716731
  31. ARID1A loss lacks prognostic significance in early stage colorectal adenocarcinoma. PMID: 26980037
  32. ARID1A may play an important role in the early events of gastric carcinogenesis. PMID: 28031120
  33. loss of ARID1A is more common in advanced GC and is related to EBV positivity and MMR deficiency PMID: 26067140
  34. ARID1A protein and mRNA expression was lower in intrahepatic cholangiocarcinoma tissue than in normal liver tissue. PMID: 27433094
  35. Most HCCs had an increased level of ARID1A mRNA. PMID: 26589513
  36. loss of ARID1A protein expression found in TU-OC-2 cells. PMID: 26960408
  37. Inactivating mutations in ARID1A may be involved in a novel pathway of carcinogenesis in biliary carcinomas PMID: 27334809
  38. loss of ARID1A shortened time to cancer-specific mortality, and to recurrence of cancer when adjusting for potential confounders (Meta-Analysis) PMID: 26384299
  39. loss of ARID1A protein expression caused by inactivating mutations reactivates TERT transcriptional activity and confers a survival advantage of tumor cells by maintaining their telomeres. PMID: 26953344
  40. All cases with ARID1A expression are overlapped with H2B high expression. Among 15 cases with ARID1A and H2B coexpression, 13 are invasive ductal carcinoma and 2 are mucinous carcinoma. Our results indicate that ARID1A gene may be involved in carcinogenesis of some subtypes of breast cancer. PMID: 26904685
  41. The action of ARID1A in carcinogenesis differs between adenofibroma-related clear cell carcinoma and endometriosis-related clear cell carcinoma. PMID: 25913291
  42. we focus on the relationships of ARID1A mutations with ovarian and endometrial cancers[review] PMID: 26572704
  43. analysis of ARID1A, CDH1, cMET and PIK3CA expression and target-related microRNA expression in gastric cancer PMID: 26334097
  44. The loss of ARID1A was correlated with late-stage and endometriosis-associated ovarian clear cell carcinoma. ARID1A expression may predict the risk of recurrence. PMID: 26945423
  45. Complete or partial loss of ARID1A expression is considered an independent poor prognostic factor in patients with gastric cancer. PMID: 26826411
  46. ARID1A positively regulates Klf15 expression with PGR to inhibit epithelial proliferation at peri-implantation. Our results suggest that Arid1a has a critical role in modulating epithelial proliferation which is a critical requisite for fertility PMID: 26378916
  47. Our results indicate that the Arid1a tumour suppressor gene has a key role in regulating ovarian endometrioid carcinoma differentiation PMID: 26279473
  48. Arid1A role in genome-wide transcriptional regulation by SWI/SNF complexes. PMID: 26716708
  49. Identification of this undescribed functional NLS within ARID1A contributes vital insights to rationalize the impact of ARID1A missense mutations observed in patient tumors. PMID: 26614907
  50. Data showed that ARID1A interacts with ATR via its C-terminal region, which mediates its recruitment to DNA double-strand breaks. PMID: 26069190
  51. Alteration of ARID1A may accelerate tumor growth in a subset of hepatocellular carcinoma, and this pathway may be distinct from p53 and beta-catenin pathways. PMID: 26045782
  52. Loss of ARID1A-encoded protein seems to be an early event in EOAC, along with pAKT activation, alteration of gammaH2AX, and concomitant activation of the apoptosis pathway. PMID: 25912412
  53. gene mutation of ARID1A led to absence of the encoded protein and inactivation of the tumor suppressor.We found that FIGO stage I and II patients with negative tumor expression of ARID1A might have a worse prognosis. PMID: 25744580
  54. Decreased expression of ARID1A was associated with tumor progression, metastasis, and reduced overall survival in mice and humans. PMID: 25975202
  55. The findings demonstrated a correlation between ARID1A expression and adenomatous differentiation of uterine squamous cell carcinomas. Therefore, ARID1A gene may have a role in the pathogenesis of cervical adenosquamous carcinomas. PMID: 26303865
  56. About 25% of urothelial carcinoma showed loss-of-function mutations of ARID1A. PMID: 26138514
  57. In small intestinal carcinoma, low or loss of ARID1A expression is correlated significantly with a high-grade tumour, higher T stage, and poorer overall survival PMID: 25400081
  58. Loss of ARID1A expression was more common in endometrial endometrioid adenocarcinomas than in ovarian endometrioid adenocarcinomas. PMID: 25195947
  59. Phosphorylation level of ARID1A at Ser696 in ovarian clear cell adenocarcinoma PMID: 25083560
  60. Suggest that the AIRD1A inactivation is associated with lymphatic invasion, lymph node metastasis, poor prognosis, and MMR deficiency in gastric adenocarcinomas. PMID: 25717252
  61. ARID1A protein loss is associated with clinicopathologic characteristics in colorectal cancer patients and with survival in stage IV patients. PMID: 25561809
  62. Complete loss of ARID1A expression by immunohistochemistry is highly specific for carcinoma; can be used in peritoneal washings to confirm malignancy in patients with endometrial carcinoma. PMID: 25557364
  63. BAF complex gene ARID1A is mutated in Coffin-Siris syndrome patients. PMID: 25081545
  64. Genotype-phenotype correlation of Coffin-Siris syndrome caused by mutations in ARID1A gene. PMID: 25168959
  65. reduced ARID1A expression in tumor tissues contributes to infiltrative growth of esophageal squamous cell carcinoma, irrespective of E-cadherin PMID: 25757668
  66. Genetic association replicative and exploratory studies identify SNPs in ADA and MTR highly associated with isolated Neural tube defects (NTD)and SNP in ARID1A and ALDH1A2 associated with NTDs in whites and African Americans respectively. PMID: 25293959
  67. Loss of AT-rich interactive domain 1A expression is associated with gastrointestinal malignancies. PMID: 25503393
  68. A significant trend of association was found between histologic grade and ARID1A expression PMID: 25776029
  69. Decreased ARID1A expression was associated with the higher nuclear grade and higher pTNM stage in clear cell renal cell carcinoma. PMID: 25628030
  70. ARID1A was not detected in liver cancer stem cells. PMID: 24944491
  71. The loss of BAF250a expression does not have prognostic value for endometrial carcinoma. PMID: 24557437
  72. our results suggest that ARID1A loss may be linked to a specific subset of sporadic microsatellite unstable colorectal carcinomas that may be medullary but is more likely to present with metastatic disease, warranting further investigation. PMID: 25311944
  73. in invasive urothelial carcinoma of urinary bladder, low ARID1A expression showed a tendency for lower risk of tumor progression and cancer mortality. PMID: 25175170
  74. In human cancer, ARID1A possesses not only features of a gatekeeper, regulating cell cycle progression, but also features of a caretaker, preventing genomic instability. [Review] PMID: 24618703
  75. ARID1A mutations were negatively associated with TP53 mutations but were unrelated to mismatch repair gene mutations in high-grade endometrial cancers PMID: 23887303
  76. loss of ARID1A expression occurs in a small but significant proportion of colorectal carcinomas where it is strongly correlated with mismatch repair deficiency PMID: 24925223
  77. ARID1A may serve as an important tumor suppressor in NSCLC. PMID: 24566899
  78. The newly identified miR-31/ARID1A pathway provides insight into cervical cancer progression. PMID: 24793973
  79. ARID1A/BAF250a may be of prognostic significance in a subset of patients with early stage gastric cancer PMID: 24767857
  80. Mutations in ARID1A gene is associated with microsatellite unstable colorectal cancer. PMID: 24382590
  81. The BAF complex, including both ARID1A and ARID1B, contributes to DNA repair and cellular resistance to ionizing radiation and cisplatin. PMID: 24788099
  82. BAF250a-encoding ARID1A has the capacity to play a tumor-suppressive role in breast cancer. PMID: 24430365
  83. Loss of ARID1A expression, PI3K-Akt pathway alterations, TP53 status and microsatellite instability are involved in endometrial cancer. PMID: 23702729
  84. ARID1A and E-cadherin expression show a strong correlation in 75.4% of the analyzed GC tissues. They are synergistically downregulated in 23.5% of analyzed GC tissues PMID: 24293408
  85. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. PMID: 24435047
  86. loss of ARID1A and ARID1B alleles cooperatively promotes cancer formation but also results in a unique functional dependence PMID: 24562383
  87. The occurrence of ARID1A mutations and alterations in the PI3K/AKT pathway in endometriosis and endometriosis-associated ovarian carcinomas, as well as the possible functional and clinical implications are discussed in this review. PMID: 24036443
  88. Loss of BAF250a expression has no prognostic significance in endometrial clear cell carcinomas PMID: 23524907
  89. Data indicate enhanced cell growth, proliferation and invasion were observed on ARID1A knockdown in esophageal adenocarcinoma (EAC) cells. PMID: 23318448
  90. Frequent inactivating mutations in multiple chromatin-remodeling genes (including BAP1, ARID1A and PBRM1), and mutation in one of these genes occurred in almost half of the carcinomas sequenced. PMID: 24185509
  91. Suggest that loss of ARID1A expression, presumably due to mutation, plays an important role in tumor progression of uterine endometrioid carcinoma. PMID: 24076775
  92. ARID1A inactivation is a key player in bladder carcinogenesis occurring predominantly in FGFR3 wild type tumors. PMID: 23650517
  93. The loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. PMID: 23427874
  94. Loss of ARID1A appears to be an early event in the carcinogenesis of endometrioid uterine carcinomas and the association with deep myometrial infiltration may suggest an importance for invasiveness. PMID: 23080032
  95. both the protein and mRNA levels of ARID1A are statistically significant prognostic markers for clear cell renal cell carcinoma. PMID: 23416164
  96. Data indicate that promoter hypermethylation was the main culprit for ARID1A mRNA low expression in invasive ductal carcinomas. PMID: 23349767
  97. study demonstrates that in-frame indel mutations of ARID1A, are associated with the loss of ability to suppress cellular proliferation and activate CDKN1A (p21) transcription PMID: 23097632
  98. Inactivating mutations of the ARID1A tumor suppressor gene are the most common in endometriosis related ovarian neoplasms. PMID: 23232571
  99. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. PMID: 22976498
  100. ARID1A may play an important role in gastric cancer. PMID: 22808142

Show More

Hide All

Involvement in disease Coffin-Siris syndrome 2 (CSS2)
Subcellular Location Nucleus
Tissue Specificity Highly expressed in spleen, thymus, prostate, testis, ovary, small intestine, colon, and PBL, and at a much lower level in heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas.
Database Links

HGNC: 11110

OMIM: 603024

KEGG: hsa:8289

STRING: 9606.ENSP00000320485

UniGene: Hs.468972

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1